The structure and function of the glucagon-like peptide-1 receptor and its ligands

British Journal of Pharmacology

Volumn 166, Issue 1, 2012, Pages 27-41

  Donnelly, Dan ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

diabetes; exenatide; exendin 4; GLP 1; glucagon; GPCR; insulin; liraglutide

Indexed keywords

EXENDIN 4; G PROTEIN COUPLED RECEPTOR; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCOSE;

AMINO ACID SUBSTITUTION; AMINO TERMINAL SEQUENCE; BLOOD GLUCOSE MONITORING; DIETARY INTAKE; DRUG MECHANISM; GLUCOSE BLOOD LEVEL; LIGAND BINDING; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN STRUCTURE; RECEPTOR BINDING; REVIEW; SEQUENCE ALIGNMENT; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION;

ANIMALS; DIABETES MELLITUS, TYPE 2; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; LIGANDS; PEPTIDES; PROTEIN CONFORMATION; RECEPTORS, GLUCAGON;

EID: 84857772149     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2011.01687.x     Document Type: Review

References (139)

1. Adelhorst K, Hedegaard BB, Knudsen LB, Kirk O, (1994). Structure-activity studies of glucagon-like peptide-1. J Biol Chem 269: 6275-6278.
2. Ahrén B, (2011). GLP-1 for type 2 diabetes. Exp Cell Res 317: 1239-1245.
3. Al-Sabah S, Donnelly D, (2003a). A model for receptor-peptide binding at the glucagon-like peptide-1 (GLP-1) receptor through the analysis of truncated ligands and receptors. Br J Pharmacol 140: 339-346.
4. Al-Sabah S, Donnelly D, (2003b). The positive charge at Lys-288 of the glucagon-like peptide-1 (GLP-1) receptor is important for binding the N-terminus of peptide agonists. FEBS Lett 553: 342-346.
5. Al-Sabah S, Donnelly D, (2004). The primary ligand-binding interaction at the GLP-1 receptor is via the putative helix of the peptide agonists. Protein Pept Lett 11: 9-14.
6. Andersen NH, Brodsky Y, Neidigh JW, Prickett KS, (2002). Medium-dependence of the secondary structure of exendin-4 and glucagon-like-peptide-1. Bioorg Med Chem 10: 79-85.
7. Bahekar RH, Jain MR, Gupta AA, Goel A, Jadav PA, Patel DN, et al,. (2007). Synthesis and antidiabetic activity of 3,6,7-trisubstituted-2-(1H- imidazol-2-ylsulfanyl)quinoxalines and quinoxalin-2-yl isothioureas. Arch Pharm (Weinheim) 340: 359-366.
8. Baldwin JM, (1993). The probable arrangement of the helices in G protein-coupled receptors. EMBO J 12: 1693-1703.
9. Bazarsuren A, Grauschopf U, Wozny M, Reusch D, Hoffmann E, Schaefer W, et al,. (2002). In vitro folding, functional characterization, and disulfide pattern of the extracellular domain of human GLP-1 receptor. Biophys Chem 96: 305-318.
10. Beinborn M, Worrall CI, McBride EW, Kopin AS, (2005). A human glucagon-like peptide-1 receptor polymorphism results in reduced agonist responsiveness. Regul Pept 130: 1-6.
11. Bergwitz C, Gardella TJ, Flannery MR, Potts JT, Kronenberg HM, Goldring SR, et al,. (1996). Full activation of chimeric receptors by hybrids between parathyroid hormone and calcitonin. J Biol Chem 271: 26469-26472.
12. Burcelin R, Dolci W, Thorens B, (1999). Long-lasting antidiabetic effect of a Dipeptidyl peptidase IV-resistant analog of glucagon-like peptide-1. Metabolism 48: 252-258.
13. Chen D, Liao J, Li N, Zhou C, Liu Q, Wang G, et al,. (2007). A non-peptidic agonist of glucagon-like peptide 1 receptors with efficacy in diabetic db/db mice. Proc Natl Acad Sci U S A 104: 943-948.
14. Chen Q, Pinon DI, Miller LJ, Dong M, (2009). Molecular basis for glucagon-like peptide 1 docking to its intact receptor studied with carboxyl-terminal photolabile probes. J Biol Chem 284: 34135-34144.
15. Chen Q, Miller LJ, Dong M, (2010a). Role of N-linked glycosylation in biosynthesis, trafficking, and function of the human glucagon-like peptide 1 receptor. Am J Physiol Endocrinol Metab 299: E62-E68.
16. Chen Q, Pinon DI, Miller LJ, Dong M, (2010b). Spatial approximations between residues 6 and 12 in the amino-terminal region of glucagon-like peptide 1 and its receptor. J Biol Chem 285: 24508-24518.
17. Coopman K, Huang Y, Johnston N, Bradley SJ, Wilkinson GF, Willars GB, (2010). Comparative effects of the endogenous agonist glucagon-like peptide-1 (GLP-1)-(7-36) amide and the small-molecule ago-allosteric agent 'Compound 2' at the GLP-1 receptor. J Pharmacol Exp Ther 334: 795-808.
18. Cornu M, Thorens B, (2009). GLP-1 protects beta-cells against apoptosis by enhancing the activity of an IGF-2/IGF1-receptor autocrine loop. Islets 1: 280-282.
19. D'Alessio DA, Kahn SE, Leusner CR, Ensinck JW, (1994). Glucagon-like peptide 1 enhances glucose tolerance both by stimulation of insulin release and by increasing insulin-independent glucose disposal. J Clin Invest 93: 2263-2266.
20. D'Alessio DA, Prigeon RL, Ensinck JW, (1995). Enteral enhancement of glucose disposition by both insulin-dependant and insulin-independent processes. A physiological role of glucagon-like peptide I. Diabetes 44: 1433-1437.
21. Day JW, Ottaway N, Patterson JT, Gelfanov V, Smiley D, Gidda J, et al,. (2009). A new glucagon and GLP-1 co-agonist eliminates obesity in rodents. Nat Chem Biol 5: 749-757.
22. Day JW, Li P, Patterson JT, Chabenne J, DiMarchi Chabenne M, Gelfanov VM, et al,. (2010). Charge inversion at position 68 of the glucagon and glucagon-like peptide-1 receptors supports selectivity in hormone action. J Pept Sci 17: 218-225.
23. Deacon CF, Johnsen AH, Holst JJ, (1995). Degradation of glucagon-like peptide01 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab 80: 952-957.
24. Deacon CF, Knudsen LB, Madsen K, Wiberg FC, Jacobsen O, Holst JJ, (1998). Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity. Diabetologia 41: 271-278.
25. Devigny C, Perez-Balderas F, Hoogeland B, Cuboni S, Wachtel R, Mauch CP, et al,. (2011). Biomimetic screening of class-B G protein-coupled receptors. J Am Chem Soc 133: 8927-8933.
26. Dillon JS, Tanizawa Y, Wheeler MB, Leng X-H, Ligon BB, Rabin DU, et al,. (1993). Cloning and functional expression of the human glucagon-like peptide-1 (GLP-1) receptor. Endocrinology 133: 1907-1910.
27. Dong M, Pinon DI, Asmann YW, Miller LJ, (2006). Possible endogenous agonist mechanism for the activation of secretin family G protein-coupled receptors. Mol Pharm 70: 206-213.
28. Dong M, Gao F, Pinon DI, Miller LJ, (2008). Insights into the structural basis of endogenous agonist activation of family B G protein-coupled receptors. Mol Endocrinol 22: 1489-1499.
29. Donnelly D, (1997). The arrangement of the transmembrane helices in the secretin receptor family of G-protein-coupled receptors. FEBS Lett 409: 431-436.
30. Donnelly D, Johnson MS, Blundell TL, Saunders J, (1989). An analysis of the periodicity of conserved residues in sequence alignments of G-protein coupled receptors. FEBS Lett 251: 109-116.
31. Donnelly D, Findlay JBC, Blundell TL, (1994). The evolution and structure of aminergic G protein-coupled receptors. Receptors Channels 2: 61-78.
32. Doyle ME, Egan JM, (2007). Mechanisms of action of glucagon-like peptide 1 in the pancreas. Pharmacol Ther 113: 546-593.
33. Doyle ME, Theodorakis MJ, Holloway HW, Bernier M, Greig NH, Egan JM, (2003). The importance of the nine-amino acid C-terminal sequence of exendin-4 for binding to the GLP-1 receptor and for biological activity. Regul Pept 114: 153-158.
34. Drucker DJ, Philippe J, Mojsov S, Chick WL, Habener JF, (1987). Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line. Proc Natl Acad Sci U S A 84: 3434-3438.
35. Edwards CMB, Todd JF, Mahmoudi M, Wang Z, Wang RM, Ghatei MA, et al,. (1999). Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans. Diabetes 48: 86-93.
36. Egan JM, Meneilly GS, Habener JF, Elahi D, (2002). Glucagon-like peptide-1 augments insulin-mediated glucose uptake in the obese state. J Clin Endocrinol Metab 87: 3768-3773.
37. Elahi D, Egan JM, Shannon RP, Meneilly GS, Khatri A, Habener JF, et al,. (2008). GLP-1 (9-36) amide, cleavage product of GLP-1 (7-36) amide, is a glucoregulatory peptide. Obesity 16: 1501-1509.
38. Eng J, Andrews PC, Kleinman WA, Singh L, Raufman J-P, (1990). Purification and structure of exendin-3, a new pancreatic secretagogue isolated from Heloderma horridum venom. J Biol Chem 265: 20259-20262.
39. Eng J, Kleinman WA, Singh L, Singh G, Raufman J-P, (1992). Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. J Biol Chem 267: 7402-7405.
40. Flint A, Raben A, Astrup A, Holst JJ, (1998). Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest 101: 515-520.
41. Frimurer TM, Bywater RP, (1999). Structure of the intergral membrane domain of the GLP1 receptor. Proteins 35: 375-386.
42. Gallwitz B, Schmidt WE, Conlon JM, Creutzfeldt W, (1990). Glucagon-like peptide-1 (7-36) amide: characterization of the domain responsible for binding to its receptor on rat insulinoma RINm5F cells. J Mol Endocrinol 5: 33-39.
43. Gallwitz B, Witt M, Paetzold G, Morays-Wortmann C, Zimmermann B, Eckart K, et al,. (1994). Structure/activity characterization of glucagon-like peptide-1. Eur J Biochem 225: 1151-1156.
44. Göke R, Fehmann H-C, Linn T, Schmidt H, Krause M, Eng J, et al,. (1993). Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting β-cells. J Biol Chem 268: 19650-19655.
45. Göke R, Just R, Lankat-Buttgereit B, Göke B, (1994). Glycosylation of the GLP-1 receptor is a prerequisite for regular receptor function. Peptides 15: 675-681.
46. Gong N, Ma A-N, Zhang L-J, Luo X-S, Zhang Y-H, Xu M, et al,. (2011). Site-specific PEGylation of exenatide analogues markedly improved their glucoregulatory activity. Br J Pharmacol 163: 399-412.
47. Graziano MP, Hey PJ, Borkowski D, Chicchi GG, Strader CD, (1993). Cloning and functional expression of a human glucagon-like peptide-1 receptor. Biochem Biophys Res Commun 196: 141-146.
48. Hällbrink M, Holmqvist T, Olsson M, Östenson C-G, Efendic S, Langel Ü, (2001). Different domains in the third intracellular loop of the GLP-1 receptor are responsible for Gαs and Gαi/Gαo activation. Biochim Biophys Acta 1546: 79-86.
49. Hansen L, Deacon CF, ørskov C, Holst JJ, (1999). Glucagon-LikePeptide-1-(7-36) amide is transformed to glucagon-like peptide-1-(9-36) amide by Dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine. Endocrinology 140: 5356-5363.
50. Hareter A, Hoffman E, Bode H-P, Göke B, Göke R, (1997). The positive charge of the imidazole side chain of Histidine7 is crucial for GLP-1 action. Endocr J 44: 701-705.
51. Harikumar KG, Pinon DI, Miller LJ, (2007). Transmembrane segment IV contributes a functionally important interface for oligomerization of the class II G protein-coupled secretin receptor. J Biol Chem 282: 30363-30372.
52. Harikumar KG, Ball AM, Sexton PM, Miller LJ, (2010). Importance of lipid-exposed residues in transmembrane segment four for family B calcitonin receptor homo-dimerization. Regul Pept 164: 113-119.
53. Heller RS, Kieffer TJ, Habener JF, (1996). Point mutations in the first and third intracellular loops of the glucagon-like peptide-1 receptor alter intracellular signaling. Biochem Biophys Res Commun 223: 624-632.
54. Hjorth SA, Schwartz TW, (1996). Glucagon and GLP-1 receptors: lessons from chimeric ligands and receptors. Acta Physiol Scand 157: 343-345.
55. Hjorth SA, Adelhorst K, Brogaard Pedersen B, Kirk O, Schwartz TW, (1994). Glucagon and glucagon-like peptide 1: selective receptor recognition via distinct peptide epitopes. J Biol Chem 269: 30121-30124.
56. Hoare SRJ, (2005). Mechanisms of peptide and nonpeptide ligand binding to Class B G-protein-coupled receptors. Drug Discov Today 10: 417-427.
57. Holst JJ, ørskov C, Vagn Nielsen O, Schwartz TW, (1987). Truncated glucagon-like peptide I, an insulin-releasing hormone from the distal gut. FEBS Lett 211: 169-174.
58. Huang Y, Wilkinson GF, Willars GB, (2010). Role of the signal peptide in the synthesis and processing of the glucagon-like peptide-1 receptor. Br J Pharmacol 159: 237-251.
59. Iltz JL, Baker DE, Setter SM, Campbell RK, (2006). Exenatide: an incretin mimetic for the treatment of type 2 diabetes mellitus. Clin Ther 28: 652-665.
60. Irwin DM, Satkunarajah M, Wen Y, Brubaker PL, Pederson RA, Wheeler MB, (1997). The Xenopus proglucagon gene encodes novel GLP-1-like peptides with insulinotropic properties. Proc Natl Acad Sci U S A 94: 7915-7920.
61. Irwin N, Flatt PR, Patterson S, Green BD, (2010). Insulin-releasing and metabolic effects of small molecule GLP-1 receptor agonist 6, 7-dichloro-2-methylsulfonyl-3-N-tert-butylaminoquinoxaline. Eur J Pharmacol 628: 268-273.
62. Knudsen LB, Pridal L, (1996). Glucagon-like peptide-1-(9-36) amide is a major metabolite of glucagon-like peptide-1-(7-36) amide after in vivo administration to dogs, and it acts as an antagonist on the pancreatic receptor. Eur J Pharmacol 318: 429-435.
63. Knudsen LB, Kiel D, Teng M, Behrens C, Bhumralkar D, Kodra JT, et al,. (2007). Small-molecule agonists for the glucagon-like peptide 1 receptor. Proc Natl Acad Sci U S A 104: 937-942.
64. Kolligs F, Fehmann H-C, Göke R, Göke B, (1995). Reduction of the incretin effect in rats by the glucagon-like peptide 1 receptor antagonist exendin (9-36) amide. Diabetes 44: 16-19.
65. Koole C, Wootten D, Simms J, Valant C, Sridhar R, Woodman OL, et al,. (2010). Allosteric ligands of the glucagon-like peptide 1 receptor (GLP-1R) differentially modulate endogenous and exogenous peptide responses in a pathway-selective manner: implications for drug screening. Mol Pharmacol 78: 456-465.
66. Kreymann B, Williams G, Ghatei MA, Bloom SR, (1987). Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet 330: 1300-1304.
67. Lin F, Wang R, (2009). Molecular modelling of the three-dimensional structure of GLP-IR and its interactions with several agonists. J Mol Model 15: 53-65.
68. Lõpez de Maturana R, Donnelly D, (2002). The glucagon-like peptide-1 receptor binding site for the N-terminus of GLP-1 requires polarity at Asp198 rather than negative charge. FEBS Lett 530: 244-248.
69. Lõpez de Maturana R, Willshaw A, Kuntzsch A, Rudolph R, Donnelly D, (2003). The isolated N-terminal domain of the Glucagon-like Peptide-1 (GLP-1) receptor binds exendin peptides with much higher affinity than GLP-1. J Biol Chem 278: 10195-10200.
70. Lõpez de Maturana R, Treece-Birch J, Abidi F, Findlay JB, Donnelly D, (2004). Met-204 and Tyr-205 are together important for binding GLP-1 receptor agonists but not their N-terminally truncated analogues. Protein Pept Lett 11: 15-22.
71. Mann R, Nasr N, Hadden D, Sinfield J, Abidi F, Al-Sabah S, et al,. (2007). Peptide binding at the GLP-1 receptor. Biochem Soc Trans 35: 713-716.
72. Mann RJ, Al-Sabah S, Lõpez de Maturana R, Sinfield JK, Donnelly D, (2010a). Functional coupling of Cys-226 and Cys-296 in the glucagon-like peptide-1 (GLP-1) receptor indicates a disulfide bond that is close to the activation pocket. Peptides 31: 2289-2293.
73. Mann RJ, Nasr NE, Sinfield JK, Paci E, Donnelly D, (2010b). The major determinant of exendin-4/glucagon-like peptide 1 differential affinity at the rat glucagon-like peptide 1 receptor N-terminal domain is a hydrogen bond from SER-32 of exendin-4. Br J Pharmacol 160: 1973-1984.
74. Mapelli C, Natarajan SI, Meyer JP, Bastos MM, Bernatowicz MS, Lee VG, et al,. (2009). Eleven amino acid glucagon-like peptide-1 receptor agonists with antidiabetic activity. J Med Chem 52: 7788-7799.
75. Mathi SK, Chan Y, Li X, Wheeler MB, (1997). Scanning of the Glucagon-Like Peptide-1 Receptor localizes G protein-activating determinants primarily to the N terminus of the third intracellular loop. Mol Endocrinol 11: 424-432.
76. McIntyre N, Holdsworth CD, Turner DS, (1964). New interpretation of oral glucose tolerance. Lancet 284: 20-21.
77. Miller LJ, Chen Q, Lam PC-H, Pinon DI, Sexton PM, Abagyan R, et al,. (2011). Refinement of glucagon-like peptide 1 docking to its intact receptor using mid-region photolabile probes and molecular modeling. J Biol Chem 286: 15895-15907.
78. Mojsov S, (1992). Structural requirements for biological activity of glucagon-like peptide-I. Int J Peptide Protein Res 40: 333-343.
79. Mojsov S, Heinrich G, Wilson IB, Ravazzola M, Orci L, Habener JF, (1986). Preproglucagon gene expression in pancreas and intestine diversifies at the level of post-translational processing. J Biol Chem 261: 11880-11889.
80. Mojsov S, Weir GC, Habener JF, (1987). Insulinotropin: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas. J Clin Invest 79: 616-619.
81. Montrose-Rafizadeh C, Yang H, Rodgers BD, Beday A, Pritchette LA, Eng J, (1997). High potency antagonists of the pancreatic glucagon-like peptide-1 receptor. J Biol Chem 272: 21201-21206.
82. Murage EN, Schroeder JC, Beinborn M, Ahn J-M, (2008). Search for alpha-helical propensity in the receptor-bound conformation of glucagon-like peptide-1. Bioorg Med Chem 16: 10106-10112.
83. Murage EN, Gao G, Bisello A, Ahn J-M, (2010). Development of potent glucagon-like peptide-1 agonists with high enzyme stability via introduction of multiple lactam bridges. J Med Chem 53: 6412-6420.
84. Nathan DM, Schreiber E, Fogel H, Majsov S, Habener JF, (1992). Insuilinotropic action of glucagonlike peptide-I-(7-37) in diabetic and nondiabetic subjects. Diabetes Care 15: 270-276.
85. Nauck MA, Homberger E, Siegel EG, Allen RC, Eaton RP, Erbert R, et al,. (1986). Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J Clin Endocrinol Metab 63: 492-498.
86. Nauck MA, Heimesaat MM, ørskov C, Holst JJ, Erbert R, Creutzfeldt W, (1993). Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 91: 301-307.
87. Nauck MA, Wollschläger D, Werner J, Holst JJ, ørskov C, Creutzfeldt W, et al,. (1996). Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM. Diabetologia 39: 1546-1553.
88. Nauck MA, Niedereichholz U, Ettler R, Holst JJ, ørskov C, Ritzel R, et al,. (1997). Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiol 273: E981-E988.
89. Neidigh JW, Andersen NH, (2002). Peptide conformational changes induced by tryptophan-phosphocholine interactions in a micelle. Biopolymers 65: 354-361.
90. Neidigh JW, Fesinmeyer RW, Prickett KS, Andersen NH, (2001). Exendin-4 and glucagon-like-peptide-1: NMR structural comparisons in the solution and micelle-associated states. Biochemistry 40: 13188-13200.
91. Neidigh JW, Fesinmeyer RM, Andersen NH, (2002). Designing a 20-residue protein. Nat Struct Biol 9: 425-430.
92. Neumann J-M, Couvineau A, Murail S, Lacapère J-J, Jamin N, Laburthe M, (2008). Class-B GPCR activation: is ligand helix-capping the key? Trends Biochem Sci 33: 314-319.
93. Neumiller JJ, Campbell RK, (2009). Liraglutide: a once-daily incretin mimetic for the treatment of type 2 diabetes mellitus. Ann Pharmacother 43: 1433-1444.
94. ørskov C, Nielsen JH, (1988). Truncated glucagon-like peptide-1 (proglucagon 78-107 amide), an intestinal insulin-releasing peptide, has specific receptors on rat insulinoma cells (RIN 5AH). FEBS Lett 229: 175-178.
95. ørskov C, Wettergren A, Holst JJ, (1993). Biological effects and metabolic rates of glucagon-like peptide-1 7-36 amide and glucagon-like peptide-1 7-37 in healthy subjects are indistinguishable. Diabetes 42: 658-661.
96. Palczewski K, Kumasaka T, Hori T, Behnke CA, Motoshima H, Fo BA, et al,. (2000). Crystal structure of rhodopsin: a G protein-coupled receptor. Science 289: 739-745.
97. Parker JC, Andrews KM, Rescek DM, Massefski W, Andrews GC, Contillo LG, et al,. (1998). Structure-function analysis of a series of glucagon-like peptide-1 analogs. J Pept Res 52: 398-409.
98. Parthier C, Reedtz-Runge S, Rudoloh R, Stubbs MT, (2009). Passing the baton in class B GPCRs: peptide hormone activation via helix induction? Trends Biochem Sci 34: 303-310.
99. Patterson JT, Day JW, Gelfanov VM, DiMarchi RD, (2011a). Functional association of the N-terminal residues with the central region in glucagon-related peptides. J Pept Sci 17: 659-666.
100. Patterson JT, Ottaway N, Gelfanov VM, Smiley DL, Perez-Tilve D, Pfluger PT, et al,. (2011b). A novel human-based receptor antagonist of sustained action reveals body weight control by endogenous GLP-1. ACS Chem Biol 6: 135-145.
101. Perfetti R, Hui H, (2004). The role of GLP-1 in the life and death of pancreatic beta cells. Horm Metab Res 36: 804-810.
102. Prévost M, Vertongen P, Raussens V, Roberts DJ, Cnuddle J, Perret J, et al,. (2010). Mutational and cysteine scanning analysis of the glucagon receptor N-terminal domain. J Biol Chem 285: 30951-30598.
103. Raufman J-P, Singh L, Eng J, (1991). Exendin-3, a novel peptide from Heloderma horridum venom, interacts with vasoactive intestinal peptide receptors and a newly described receptor on dispersed acini from guinea pig pancreas. J Biol Chem 266: 2897-2902.
104. Raufman J-P, Singh L, Singh G, Eng J, (1992). Truncated glucagon-like peptide-1 interacts with exendin receptors on dispersed acini from guinea pig pancreas. J Biol Chem 267: 21432-21437.
105. Runge A, Schimmer S, Oschmann J, Schiødt CB, Knudsen SM, Jeppesen CB, et al,. (2007). Differential structural properties of GLP-1 and exendin-4 determine their relative affinity for the GLP-1 receptor N-terminal extracellular domain. Biochemistry 46: 5830-5840.
106. Runge S, Gram C, Bräuner-Osborne H, Madsen K, Knudsen LB, Wulff BS, (2003a). Three distinct epitopes on the extracellular face of the glucagon receptor determine specificity for the glucagon amino terminus. J Biol Chem 278: 28005-28010.
107. Runge S, Wulff BS, Madsen K, Bräuner-Osborne H, Knudsen LB, (2003b). Different domains of the glucagon and glucagon-like peptide-1 receptors provide the critical determinants of ligand selectivity. Br J Pharmacol 138: 787-794.
108. Runge S, Thøgersen H, Madsen K, Lau J, Rudolph R, (2008). Crystal structure of the ligand-bound glucagon-like peptide-1 receptor extracellular domain. J Biol Chem 283: 11340-11347.
109. Salapatek A-MF, MacDonald PE, Gaisano HY, Wheeler MB, (1999). Mutations to the Third Cytoplasmic Domain of the Glucagon-Like Peptide 1 (GLP-1) Receptor Can Functionally Uncouple GLP-1-Stimulated Insulin Secretion in HIT-T15 Cells. Mol Endocrinol 13: 1305-1317.
110. Schepp W, Schmidtler J, Riedel T, Dehne K, Schusdziarra V, Holst JJ, et al,. (1994). Exendin-4 and exendin-(9-39)-amide: agonist and antagonist, respectively at the rat parietal cell receptor for glucagon-like peptide-1-(7-36)-amide. Eur J Pharmacol 269: 183-191.
111. Schröder-Tittmann K, Bosse-Doenecke E, Reedtz-Runge S, Ihling C, Sinz A, Tittmann K, et al,. (2010). Recombinant expression, in vitro refolding, and biophysical characterization of the human glucagon-like peptide-1 receptor. Biochemistry 49: 7956-7965.
112. Segre GV, Goldring SR, (1993). Receptors for secretin, calcitonin, parathyroid hormone (PTH)/PTH-related peptide, vasoactive intestinal peptide, glucagonlike peptide 1, growth hormone-releasing hormone, and glucagon belong to a newly discovered G-protein-linked receptor family. Trends Endocrinol Metab 4: 309-314.
113. Serre V, Dolci W, Schaerer E, Scrocchi L, Drucker D, Efrat S, et al,. (1998). Exendin-(9-39) is an inverse agonist of the murine glucagon-like peptide-1 receptor: implications for basal intracellular cyclic adenosine 3′, 5′- monophosphate levels and β-cell glucose competence. Endocrinology 139: 4448-4454.
114. Siegel EG, Gallwitz B, Scharf G, Mentlein R, Morys-Wortmann C, Fölsch UR, et al,. (1999). Biological activity of GLP-1-analogues with N-terminal modifications. Regul Pept 79: 93-102.
115. Sloop KW, Willard FS, Brenner MB, Ficorilli J, Valasek K, Showalter AD, et al,. (2010). Novel small molecule glucagon-like peptide-1 agonist stimulates insulin secretion in rodents and from human islets. Diabetes 59: 3099-3107.
116. Su H, He M, Li H, Liu Q, Wang J, Wang Y, et al,. (2008). Boc5, a non-peptidic glucagon-like peptide-1 receptor agonist, invokes sustained glycemic control and weight loss in diabetic mice. PLoS ONE 3: 1-11.
117. Suzuki S, Kawai K, Ohashi S, Mukai H, Yamashita K, (1989). Comparison of the effects of various C-terminal and N-terminal fragment peptides of glucagon-like peptide-1 on insulin and glucagon release from the isolated perfused rat pancreas. Endocrinology 125: 3109-3114.
118. Syme CA, Zhang L, Bisello A, (2006). Caveolin-1 regulates cellular trafficking and function in the glucagon-like peptide 1 receptor. Mol Endocrinol 20: 3400-3411.
119. Takhar A, Gyomorey S, Su R-C, Mathi SK, Li X, Wheeler MB, (1995). The third cytoplasmic domain of the GLP-1[7-36 amide] receptor is required for coupling to the adenylyl cyclase system. Endocrinology 137: 2175-2178.
120. Tams JW, Knudsen SM, Fahrenkrug J, (1998). Proposed arrangement of the seven transmembrane helices in the secretin receptor family. Receptors Channels 5: 79-90.
121. Teng M, Johnson MD, Thomas C, Kiel D, Lakis JN, Kercher T, et al,. (2007). Small molecule ago-allosteric modulators of the human glucagon-like peptide-1 (hGLP-1) receptor. Bioorg Med Chem Lett 17: 5472-5478.
122. Thorens B, (1992). Expression cloning of the pancreatic β cell receptor for the gluco-incretin hormone glucagon-like peptide 1. Proc Natl Acad Sci U S A 89: 8641-8645.
123. Thorens B, Porett A, Bühler L, Deng SP, Morel P, Widmann C, (1993). Cloning and functional expression of the human islet GLP-1 receptor. Demonstration that exendin-4 is an agonist and exendin-(9-39) an antagonist of the receptor. Diabetes 42: 1678-1682.
124. Thornton K, Gorenstein DG, (1994). Structure of glucagon-like peptide (7-36) amide in a dodecylphosphocholine micelle as determined by 2D NMR. Biochemistry 33: 3532-3539.
125. Tibaduiza EC, Chen C, Beinborn M, (2001). A small molecule ligand of the glucagon-like peptide 1 receptor targets its amino-terminal hormone binding domain. J Biol Chem 276: 37787-37793.
126. Turton MD, O'Shea D, Gunn I, Beak SA, Edwards CMB, Meeran K, et al,. (1996). A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 379: 69-72.
127. Underwood CR, Garibay P, Knudsen LB, Hastrup S, Peters GH, Rudolph R, et al,. (2010). Crystal structure of glucagon-like peptide-1 in complex with the extracellular domain of the glucagon-like peptide-1 receptor. J Biol Chem 285: 723-730.
128. Vahl TP, Paty BW, Fuller BD, Prigeon RL, D'Alessio DA, (2003). Effects of GLP-1-(7-36) amide, GLP-1-(7-37), and GLP-1-(9-36) amide on intravenous glucose tolerance and glucose-induced insulin secretion in healthy humans. J Clin Endocrinol Metab 88: 1772-1779.
129. Wang S, Yu J, Li W, Li F, (2010). Structural study of an active analog of EX-4 in solution and micelle associated states. Biopolymers (Peptide Science) 96: 348-357.
130. Watanabe Y, Kawai K, Oshashi S, Yokota C, Suzuki S, Yamashita K, (1994). Structure-activity relationships of glucagon-like peptide-1 (7-36) amide: insulinotropic activities in perfused rat pancreases, and receptor binding and cyclic AMP production in RINm5F cells. J Endocrinol 140: 45-52.
131. Weir GC, Mojsov S, Hendrick GK, Habener JF, (1989). Glucagon-like peptide I (7-37) actions on endocrine pancreas. Diabetes 38: 338-342.
132. Wettergren A, Schjoldager B, Mortensen PE, Myhre J, Christiansen J, Holst JJ, (1993). Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man. Dig Dis Sci 38: 665-673.
133. Widmann C, Dolci W, Thorens B, (1995). Agonist-induced internalization and recycling of the glucagon-like peptide-1 receptor in transfected fibroblasts and in insulinomas. Biochem J 310: 203-214.
134. Widmann C, Dolci W, Thorens B, (1996a). Desensitization and phosphorylation of the glucagon-like peptide-1 (GLP-1) receptor by GLP-1 and 4-Phorbol 12-Myristate 13-Acetate. Mol Endocrinol 10: 62-75.
135. Widmann C, Dolci W, Thorens B, (1996b). Heterologous desensitization of the glucagon-like peptide-1 receptor by phorbol esters requires phosphorylation of the cytoplasmic tail at four different sites. J Biol Chem 271: 19957-19963.
136. Wilmen A, Göke B, Göke R, (1996). The isolated N-terminal extracellular domain of the glucagon-like peptide-1 (GLP)-1 receptor has intrinsic binding activity. FEBS Lett 398: 43-47.
137. Wootten D, Simms J, Koole C, Woodman OL, Summers RJ, Christopoulos A, et al,. (2011). Modulation of the glucagon-like peptide-1 receptor signaling by naturally occurring and synthetic flavonoids. J Pharmacol Exp Ther 336: 540-550.
138. Xiao Q, Jeng W, Wheeler MB, (2000). Characterization of glucagon-like peptide-1 receptor binding determinants. J Mol Endocrinol 25: 321-335.
139. Xiao Q, Giguere J, Parisen M, Jeng WS, Pierre PL, Brubaker PL, et al,. (2001). Biological activities of glucagon-like peptide-1 analogues in vitro and in vivo. Biochemistry 40: 2860-2869.